

INSTITUTIONAL BIOSAFETY COMMITTEE REVIEW

MEETING MINUTES

Meeting Date: Tuesday, March 3, 2026
Time: 1:00 pm Eastern Time
Location: Zoom Teleconference
Institution: BriaCell Therapeutics Corp., Philadelphia, PA
Principal Investigator: Ying Liu, PhD, MS
Project: BriaCell Therapeutics, Corp., Bria-1A/B
Meeting Type: Modification Review of Project
Title: Creation, Testing, and Use of Lentiviral Vectors for Tumor Cell Engineering

1. Call to order:

The Meeting was called to order at 1:00 pm Eastern Time.

2. Introductions and orientation:

Introductions were made and the Chair oriented members to the meeting procedures.

3. Declaration of quorum:

Five voting members were present, including two local members unaffiliated with the institution. Also present were four Institutional Representatives, the Principal Investigator, and IBC Services staff. The Chair declared that a quorum was present.

4. Conflict of Interest:

The Chair requested that voting members report any conflict of interest regarding this meeting. No conflicts of interest were reported.

5. Public posting:

An Institutional Representative confirmed that notice of the meeting was publicly posted. No public comments were received by the site or the Committee regarding this review.

6. Approval of previous meeting minutes:

Minutes Approved - YES: 4 NO: 0 ABSTAIN: 1

7. Review of proposed research:

The Chair provided an overview of the project.

The Chair and Principal Investigator provided an overview of the proposed modifications.

Points of Discussion:

1. The Committee discussed the previously IBC approved BSL-2+ practices. The Biosafety Officer stated that the autoclave is not validated for sterilizing waste as it is only used for glassware and noted that using it for waste may be added risk in terms of handling the materials more than they do now.
2. The Committee discussed the distinction between BSL-2 and BSL-2+ handling at the institution. The Principal Investigator stated that both indicate that work is done inside a Biological Safety Cabinet (BSC), but that BSL-2+ also includes use of double gloves, secondary containers for internal transport, and aerosol protection measures, such as centrifuge safety cups and opening containers within a BSC. The Committee found these to be acceptable.
3. The Principal Investigator requested to store research materials in an unlocked freezer within a storage room that is accessible via badge only. The Committee found this to be acceptable.

8. Determination for biosafety level and period of IBC oversight:

The Committee previously determined that **BSL-2 containment facilities and practices** are required for all work with human cells and replication-defective lentiviral vectors.

The Committee determined that **BSL-2+ containment facilities and practices** are required for the creation of lentiviral vectors and replication competency testing, including the use of R8.71. BSL-2+ includes the use of double

INSTITUTIONAL BIOSAFETY COMMITTEE REVIEW

gloves, secondary containers for transport, and aerosol protection measures, including centrifuge safety cups and opening containers within a BSC.

The Committee previously determined that **IBC oversight will continue as long as the research is active at the site.**

9. Vote on project:

The Committee voted for following determination on the Project:

X	APPROVED
	CONDITIONALLY APPROVED
	TABLED
	DISAPPROVED

DETERMINATION VOTE - YES: 5 NO: 0 ABSTAIN: 0

10. Meeting adjourned: The meeting was adjourned at 1:22 pm Eastern Time.

Documents Reviewed:

Agenda

Environmental Health and Safety Manual, dated 2025

Research Modification Evaluation, Site Practices Change, dated 02-24-2026

Site Map, dated 02-27-2026

Site Inspection Checklist, dated 01-26-2026, updated 02-26-2026

Photos, dated 02-27-2026

Prior Meeting Minutes, Bria - 1A/B, Initial, dated 02-19-2026